Immunocore Holdings Performance degli utili passati
Criteri Il passato verificati 0/6
Immunocore Holdings ha registrato una crescita degli utili a un tasso medio annuo di 35.5%, mentre il settore Biotechs ha registrato utili in crescita a un tasso medio annuo di 33.8%. I ricavi sono stati in crescita a un tasso medio annuo di 38.5%.
Informazioni chiave
35.49%
Tasso di crescita degli utili
43.36%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.04% |
| Tasso di crescita dei ricavi | 38.55% |
| Rendimento del capitale proprio | -7.00% |
| Margine netto | -6.68% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento della narrazione • May 19
IMCR: Future Upside Will Depend On Risky Oncology Pipeline Execution
Analysts now set Immunocore Holdings' fair value at $34, up $1 from $33. This reflects adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E after recent Street research highlighted a more cautious view on upside without clearer pipeline progress.Aggiornamento della narrazione • Apr 25
IMCR: Pipeline Upside Will Rely On Higher Risk Oncology Programs
Analysts cut their price target on Immunocore Holdings to $33 from $48, noting that Kimmtrak provides an established revenue base in uveal melanoma. They indicated that the investment case now depends more on what they view as higher risk pipeline outcomes.Aggiornamento della narrazione • Apr 08
IMCR: Pipeline Risk And Sector Rotation Will Shape Balanced 2026 Outlook
Analysts have reset their average price target on Immunocore to $33. Some frame this move as a sign that Kimmtrak's uveal melanoma revenue potential is closer to peak, with future upside hinging more on higher risk pipeline assets, while others still see room for value in the broader small to mid cap biotech group.Aggiornamento della narrazione • Mar 24
IMCR: Sector Rotation And Pipeline Risk Will Shape Balanced 2026 Outlook
Narrative Update The analyst fair value estimate for Immunocore Holdings has shifted from $38 to $33. This change reflects mixed Street views, with some analysts highlighting Kimmtrak's moderate market and maturing sales, while others point to broader biotech sentiment and pipeline potential as key factors for future returns.Aggiornamento della narrazione • Mar 10
IMCR: Sector Rotation And Capital Production Shift Will Shape Bullish 2026 Outlook
Analysts have nudged their fair value estimate for Immunocore Holdings up from $37.00 to $38.00, citing higher Street price targets from $40 to $55. These targets reflect growing confidence in small to mid cap biotech as some companies are seen as shifting from capital consumers to capital producers and benefiting from improving sector sentiment.
Aggiornamento della narrazione • Feb 24
IMCR: Bullish View Will Center On 2026 Capital Producer Transition
Analysts have nudged their average price target on Immunocore higher, with recent moves such as a lift to $40 and an upgrade anchored by a new $55 target. These changes support a small upward adjustment in our modeled fair value to $66.57, alongside slightly higher discount rate and P/E assumptions.Aggiornamento della narrazione • Feb 08
IMCR: Sector Rotation And Pipeline Execution Will Shape Bullish 2026 Outlook
Narrative Update on Immunocore Holdings Analysts have lifted their average price target for Immunocore to a range anchored by the recent US$40 and US$55 targets. This reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples as they factor in improving sentiment toward small to mid cap biotech names.Aggiornamento della narrazione • Jan 24
IMCR: Balanced Outlook As Hepatitis B Data And Sector Rotation Shape 2026
Analysts have lifted their price target framework for Immunocore Holdings from about $24.93 to $37.00, reflecting recent Street research in which firms increased targets to as high as $55 and highlighted improving biotech fundamentals along with shifting investor attention toward small to mid cap commercial names. Analyst Commentary Recent Street research on Immunocore Holdings clusters around a common theme, with several firms linking their updated views to a broader shift in attention toward small to mid cap commercial biotech names.Aggiornamento della narrazione • Jan 10
IMCR: Bullish View Will Center On Advancing HBV TCR Bispecific Program
Narrative Update Analysts have lifted their blended price target for Immunocore, with recent moves such as a Morgan Stanley increase to $40 and a UBS move to $55 contributing to a higher implied fair value of about $66.36, based on updated assumptions for growth, margins and a higher future P/E multiple. Analyst Commentary Recent Street research around Immunocore centers on shifting views of small to mid cap biotech, updated price targets, and how investors might think about the balance between potential upside and execution risk.Seeking Alpha • Nov 08
Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst
Summary Immunocore still relies exclusively on sales of tebentafusp to fund operations. While these sales have supported the company, they have not been enough to achieve profitability. Current market sentiment says to "Hold" based on slowing sales growth, but this does not factor in the broad pipeline. To me, this is a qualified "Buy" assuming they can take any one of their many projects to the finish line. Read the full article on Seeking AlphaArticolo di analisi • Aug 02
Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jun 10
Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders have had their patience rewarded with a 27% share price jump in...Seeking Alpha • Apr 27
Immunocore Holdings: A Name On My Watch List
Summary Immunocore Holdings' shares have fallen over 60% since February 2024 due to lack of catalysts and competition for its main product, Kimmtrak. Kimmtrak, approved for metastatic uveal melanoma, faces market saturation and competition, but label expansion could significantly increase its market potential. Immunocore's pipeline includes promising early-stage oncology and infectious disease programs, but pivotal data for key trials won't be available until 2H26 or later. An analysis around Immuncore Holdings follows in the paragraphs below. Read the full article on Seeking AlphaArticolo di analisi • Apr 26
Improved Revenues Required Before Immunocore Holdings plc (NASDAQ:IMCR) Shares Find Their Feet
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 4.9x might make it look like a buy right...
Nuova narrazione • Mar 23
AI Tools And Global Expansion Will Broaden KIMMTRAK's Market Reach
Expansion into less dense U.S. markets and international launches are key to driving revenue growth for Immunocore's KIMMTRAK.Articolo di analisi • Mar 04
Is Immunocore Holdings (NASDAQ:IMCR) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 27
Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point
Summary Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential acquisition. Growth of tebentafusp sales has slowed, increasing reliance on new projects like brenetafusp, which carries inherent biotech industry risks. IMCR's financials show increased product revenue and net income, with substantial cash reserves to support ongoing and future developments. Read the full article on Seeking AlphaArticolo di analisi • Jan 08
There Is A Reason Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Undemanding
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a strong buy...Seeking Alpha • Dec 10
Immunocore Is Adequately Valued, But Its Prospects Are Uncertain
Summary Immunocore's KIMMTRAK, targeting metastatic uveal melanoma, is FDA-approved and has shown significant clinical efficacy, with potential label expansions in cutaneous and adjuvant uveal melanoma. The company's ImmTAX platform develops TCR-based bispecific molecules, with ongoing trials for Tebentafusp and Brenetafusp in various cancers, showing promising early results. Financially, Immunocore has a strong cash position and stable revenue growth, but concerns remain about the pipeline's strength and clarity. Despite recent stock declines and cautious market sentiment, future trial successes could make current prices attractive for conservative investors. Read the full article on Seeking AlphaArticolo di analisi • Oct 24
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Sep 19
Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 6.1x might make it look like a buy right...Seeking Alpha • Aug 12
Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Summary Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C for cutaneous melanoma and IMC-M113V for HIV. The main risks stem from the Company's heavy reliance on KIMMTRAK and potential clinical trial failures for other pipeline drugs, such as IMC-F106C and IMC-M113V. I also believe IMCR could be a viable takeover target, given its diverse IP, growing revenues, and strong financials, which could potentially attract big pharma. Despite premium valuation risks, Immunocore's financials are robust, making it a "buy" for long-term investors familiar with biotech risks. Read the full article on Seeking AlphaArticolo di analisi • Jul 24
Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunocore Holdings fair value estimate is US$58.75 Immunocore...Articolo di analisi • Jun 16
Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues
To the annoyance of some shareholders, Immunocore Holdings plc ( NASDAQ:IMCR ) shares are down a considerable 28% in...Articolo di analisi • May 11
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • May 11
Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders are probably feeling a little disappointed, since its shares fell...Articolo di analisi • Apr 05
Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunocore Holdings fair value estimate is US$83.30 Immunocore...Articolo di analisi • Jan 22
Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Jan 21
Immunocore Holdings: Vulnerable To Profit Taking After Big Rally
Summary Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing immunotherapies for cancer, infectious, and autoimmune diseases. The company's stock is up around 80% since late October and now is solidly in mid-cap territory. The stock has gotten shout outs from Barron's and Robert W. Baird to start the new year. Are further gains ahead in 2024 for Immunocore shareholders? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaArticolo di analisi • Dec 18
Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%
Immunocore Holdings plc ( NASDAQ:IMCR ) shares have had a really impressive month, gaining 37% after a shaky period...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Immunocore Holdings guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 413 | -28 | 163 | 271 |
| 31 Dec 25 | 400 | -36 | 165 | 266 |
| 30 Sep 25 | 380 | -29 | 165 | 214 |
| 30 Jun 25 | 356 | -20 | 161 | 214 |
| 31 Mar 25 | 334 | -22 | 157 | 213 |
| 31 Dec 24 | 310 | -51 | 156 | 214 |
| 30 Sep 24 | 296 | -47 | 155 | 157 |
| 30 Jun 24 | 281 | -55 | 155 | 157 |
| 31 Mar 24 | 265 | -60 | 151 | 215 |
| 31 Dec 23 | 249 | -55 | 144 | 157 |
| 30 Sep 23 | 237 | -69 | 164 | 0 |
| 30 Jun 23 | 220 | -61 | 141 | 0 |
| 31 Mar 23 | 201 | -52 | 131 | 0 |
| 31 Dec 22 | 174 | -53 | 123 | 97 |
| 30 Sep 22 | 114 | -62 | 84 | 0 |
| 30 Jun 22 | 82 | -112 | 101 | 0 |
| 31 Mar 22 | 53 | -156 | 116 | 0 |
| 31 Dec 21 | 36 | -180 | 111 | 0 |
| 30 Sep 21 | 37 | -150 | 105 | -78 |
| 30 Jun 21 | 39 | -139 | 94 | -51 |
| 31 Mar 21 | 42 | -116 | 78 | 0 |
| 31 Dec 20 | 41 | -101 | 63 | 0 |
| 30 Sep 20 | 37 | -105 | 52 | 106 |
| 30 Jun 20 | 34 | -109 | 55 | 102 |
| 31 Mar 20 | 33 | -120 | 53 | 90 |
| 31 Dec 19 | 34 | -138 | 59 | 0 |
| 31 Dec 18 | 30 | -91 | 44 | 107 |
| 31 Dec 17 | 19 | -66 | 29 | 81 |
| 31 Dec 16 | 20 | -29 | 5 | 57 |
| 31 Dec 15 | 17 | 20 | 4 | 33 |
Guadagni di qualità: IMCR al momento non è redditizia.
Margine di profitto in crescita: IMCR al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: IMCR non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 35.5% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di IMCR nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: IMCR non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 43% ).
Rendimento del capitale proprio
ROE elevato: IMCR ha un Return on Equity negativo ( -7% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/22 04:33 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Immunocore Holdings plc è coperta da 27 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jack Allen | Baird |
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |